Interferon ( IFN ) – g , Tumor Necrosis Factor – a , Interleukin-6 , and IFN-g Receptor 1 Are the Major Immunological Determinants Associated with Post – Kala Azar Dermal Leishmaniasis
暂无分享,去创建一个
[1] K. Sardana,et al. Postkala‐azar dermal leishmaniasis coexisting with borderline tuberculoid leprosy , 2007, The British journal of dermatology.
[2] Dhiraj Kumar,et al. Visceral leishmaniasis, or kala azar (KA): high incidence of refractoriness to antimony is contributed by anthroponotic transmission via post-KA dermal leishmaniasis. , 2006, The Journal of infectious diseases.
[3] P. Salotra,et al. Elevated levels of interferon-gamma, interleukin-10, and interleukin-6 during active disease in Indian kala azar. , 2006, Clinical immunology.
[4] M. Kaye,et al. IN VIVO AND IN VITRO , 2006 .
[5] Y. Belkaid,et al. Conditions Influencing the Efficacy of Vaccination with Live Organisms against Leishmania major Infection , 2005, Infection and Immunity.
[6] Yasmine Belkaid,et al. Natural regulatory T cells in infectious disease , 2005, Nature Immunology.
[7] P. Desjeux. Leishmaniasis: current situation and new perspectives. , 2004, Comparative immunology, microbiology and infectious diseases.
[8] J. Blackwell,et al. Genetics and visceral leishmaniasis in the Sudan: seeking a link. , 2004, Trends in parasitology.
[9] D.Y. Lee,et al. Differential in vivo cytokine mRNA expression in lesional skin of intrinsic vs. extrinsic atopic dermatitis patients using semiquantitative RT‐PCR , 2003, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[10] P. Kaye,et al. Both Interleukin-4 (IL-4) and IL-4 Receptor α Signaling Contribute to the Development of Hepatic Granulomas with Optimal Antileishmanial Activity , 2003, Infection and Immunity.
[11] E. N. Miller,et al. Genetic susceptibility to visceral leishmaniasis in The Sudan: linkage and association with IL4 and IFNGR1 , 2003, Genes and Immunity.
[12] P. Das,et al. Antileishmanial drugs cause up-regulation of interferon-gamma receptor 1, not only in the monocytes of visceral leishmaniasis cases but also in cultured THP1 cells , 2003, Annals of tropical medicine and parasitology.
[13] E. Pugh,et al. Association between the Tumor Necrosis Factor Locus and the Clinical Outcome of Leishmania chagasi Infection , 2002, Infection and Immunity.
[14] R. Coffman,et al. Interleukin-10 (IL-10) in Experimental Visceral Leishmaniasis and IL-10 Receptor Blockade as Immunotherapy , 2002, Infection and Immunity.
[15] Shyam Sundar,et al. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. , 2002, The Lancet. Infectious diseases.
[16] Y. Belkaid,et al. The Role of Interleukin (IL)-10 in the Persistence of Leishmania major in the Skin after Healing and the Therapeutic Potential of Anti–IL-10 Receptor Antibody for Sterile Cure , 2001, The Journal of experimental medicine.
[17] S. Sundar. Drug resistance in Indian visceral leishmaniasis , 2001, Tropical medicine & international health : TM & IH.
[18] F. Powrie,et al. Regulatory T cells in the control of immune pathology , 2001, Nature Immunology.
[19] H. Nakhasi,et al. Development of a Species-Specific PCR Assay for Detection of Leishmania donovani in Clinical Samples from Patients with Kala-Azar and Post-Kala-Azar Dermal Leishmaniasis , 2001, Journal of Clinical Microbiology.
[20] M. Roncarolo,et al. Differentiation of T Regulatory Cells by Immature Dendritic Cells , 2001, The Journal of experimental medicine.
[21] B. Lell,et al. Plasma interleukin-10:Tumor necrosis factor (TNF)-alpha ratio is associated with TNF promoter variants and predicts malarial complications. , 2000, The Journal of infectious diseases.
[22] H. Murray,et al. Interleukin-12 regulates the response to chemotherapy in experimental visceral Leishmaniasis. , 2000, The Journal of infectious diseases.
[23] J. Wang,et al. Consideration of cytokines as therapeutics agents or targets. , 2000, Current pharmaceutical design.
[24] P. Marrack,et al. Activation-Induced Inhibition of Interleukin 6–Mediated T Cell Survival and Signal Transducer and Activator of Transcription 1 Signaling , 2000, The Journal of experimental medicine.
[25] M. Ray,et al. Inhibition of interferon-gamma signaling by Leishmania donovani. , 2000, The Journal of infectious diseases.
[26] T. Theander,et al. Immunopathology of post kala‐azar dermal leishmaniasis (PKDL): T‐cell phenotypes and cytokine profile , 1999, The Journal of pathology.
[27] A. Allione,et al. Nitric oxide suppresses human T lymphocyte proliferation through IFN-gamma-dependent and IFN-gamma-independent induction of apoptosis. , 1999, Journal of immunology.
[28] T. Theander,et al. Leishmania‐specific T cells expressing interferon‐gamma (IFN‐γ) and IL‐10 upon activation are expanded in individuals cured of visceral leishmaniasis , 1999, Clinical and experimental immunology.
[29] T. Theander,et al. T-cell response in human leishmaniasis. , 1999, Immunology letters.
[30] P. Salotra,et al. Western blot analysis of humoral immune response to Leishmania donovani antigens in patients with post-kala-azar dermal leishmaniasis. , 1999, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[31] F. Handjani,et al. Post-kala-azar dermal leishmaniasis. , 1998, European journal of dermatology : EJD.
[32] K. Dellagi,et al. Immunologic determinants of disease evolution in localized cutaneous leishmaniasis due to Leishmania major. , 1998, The Journal of infectious diseases.
[33] S. Sundar,et al. Splenic cytokine responses in Indian kala-azar before and after treatment. , 1998, The Journal of infectious diseases.
[34] E. Zijlstra,et al. Post kala-azar ocular leishmaniasis. , 1998, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[35] T. Theander,et al. High levels of plasma IL‐10 and expression of IL‐10 by keratinocytes during visceral leishmaniasis predict subsequent development of post‐kala‐azar dermal leishmaniasis , 1998, Clinical and experimental immunology.
[36] H. Noyes,et al. Leishmania Chagasi: Genotypically Similar Parasites from Honduras Cause Both Visceral and Cutaneous Leishmaniasis in Humans , 2022 .
[37] G. Stassi,et al. In vivo and in vitro cytokine profiles and mononuclear cell subsets in Sicilian patients with active visceral leishmaniasis. , 1995, Cytokine.
[38] M. Aguet,et al. Development of antimalaria immunity in mice lacking IFN-gamma receptor. , 1995, Journal of immunology.
[39] S. Huang,et al. Mice from a genetically resistant background lacking the interferon gamma receptor are susceptible to infection with Leishmania major but mount a polarized T helper cell 1-type CD4+ T cell response , 1995, The Journal of experimental medicine.
[40] V. Ramesh,et al. Post‐kala‐azar dermal leishmaniasis , 1993, The Australasian journal of dermatology.
[41] Darnell,et al. Increased expression of proinflammatory cytokines in chronic lesions of human cutaneous leishmaniasis , 1994, Infection and immunity.
[42] R. de Waal Malefyt,et al. Expression cloning and characterization of a human IL-10 receptor. , 1994, Journal of immunology.
[43] Y. Liu,et al. A receptor for interleukin 10 is related to interferon receptors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[44] J. Sobel,et al. IL-6 down-modulates the cytokine-enhanced antileishmanial activity in human macrophages. , 1993, Journal of immunology.
[45] Mohamed,et al. Interleukin 10 production correlates with pathology in human Leishmania donovani infections. , 1993, The Journal of clinical investigation.
[46] Wynn,et al. In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-gamma. , 1993, The Journal of clinical investigation.
[47] J Sanceau,et al. Tumor necrosis factor-alpha and IL-6 up-regulate IFN-gamma receptor gene expression in human monocytic THP-1 cells by transcriptional and post-transcriptional mechanisms. , 1992, Journal of immunology.
[48] S. Reed,et al. Transforming growth factor-beta in leishmanial infection: a parasite escape mechanism. , 1992, Science.
[49] E. Zijlstra,et al. Post kala-azar dermal leishmaniasis in the Sudan: clinical features, pathology and treatment. , 1992, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[50] F. Liew,et al. Tumor necrosis factor-alpha synergizes with IFN-gamma in mediating killing of Leishmania major through the induction of nitric oxide. , 1990, Journal of immunology.
[51] Y. Leng. A review of kala-azar in China from 1949 to 1959. , 1982, Transactions of the Royal Society of Tropical Medicine and Hygiene.